Dr. Daigle graduated from the Louisiana State University School of Medicine at Shreveport in 1990. He works in Seattle, WA and specializes in Family Medicine. Dr. Daigle is affiliated with VA Puget Sound Healthcare Seattle Division.
Edward James Olhava - Newton MA, US Richard Chesworth - Boston MA, US Kevin Wayne Kuntz - Woburn MA, US Victoria M. Richon - Wellesley MA, US Roy Macfarlane Pollock - Medford MA, US Scott Richard Daigle - Newburyport MA, US
Assignee:
Epizyme, Inc. - Cambridge MA
International Classification:
A61K 31/70 C07H 19/00
US Classification:
514 46, 536 276
Abstract:
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Richard Chesworth - Concord MA, US Kevin W. Kuntz - Woburn MA, US Victoria M. Richon - Wellesley MA, US Roy M. Pollock - Medford MA, US Scott R. Daigle - Newburyport MA, US
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin W. KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott Richard DAIGLE - Newburyport MA, US
International Classification:
A61K 31/7076 A61K 31/52
Abstract:
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin W. KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott R. DAIGLE - Newburyport MA, US
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin W. KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott Richard DAIGLE - Newburyport MA, US
International Classification:
A61K 31/7076 A61K 31/52
Abstract:
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin Wayne KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott R. DAIGLE - Newburyport MA, US
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard Chesworth - Concord MA, US Kevin W. Kuntz - Woburn MA, US Victoria M. Richon - Wellesley MA, US Roy M. Pollock - Medford MA, US Scott Richard Daigle - Newburyport MA, US
International Classification:
A61K 31/7076
Abstract:
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard Chesworth - Concord MA, US Kevin Wayne Kuntz - Woburn MA, US Victoria M. Richon - Wellesley MA, US Roy M. Pollock - Medford MA, US Scott R. Daigle - Newburyport MA, US
Assignee:
EPIZYME, INC. - Cambridge MA
International Classification:
A61K 31/7076 A61K 31/519 A61K 31/52 A61K 31/7064
Abstract:
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
de-escalation techniques to handle situations that get out of control in emergency rooms. A revised version of the bill would make allowances for people with mental illness, dementia or developmental disabilities be exempt from enhanced penalties, said Howards chief of staff, Scott Daigle. SB 36